Sionna Therapeutics (SION) Accumulated Expenses (2024 - 2026)

Sionna Therapeutics (SION) has 3 years of Accumulated Expenses data on file, last reported at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 86.72% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.3 million (up 86.72% YoY), and the FY2025 full-year result was $9.7 million, up 18.45% from the prior year.
• Accumulated Expenses eased to $6.3 million in Q1 2026, from $9.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9.7 million in Q4 2025 to a low of $3.4 million in Q1 2025.
• A 3-year average of $6.7 million and a median of $6.6 million in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses increased 18.45% in 2025 and soared 86.72% in 2026, its largest moves.
• Tracing SION's Accumulated Expenses over 3 years: stood at $8.2 million in 2024, then advanced by 18.45% to $9.7 million in 2025, then tumbled by 34.55% to $6.3 million in 2026.
• Business Quant data shows SION's Accumulated Expenses at $6.3 million in Q1 2026, $9.7 million in Q4 2025, and $6.9 million in Q3 2025.